Abiraterone-d4

Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.

Product Specifications

CAS Number

[2122245-62-7]

Product Name Alternative

CB-7598-D4

UNSPSC

12352005

Target

Cytochrome P450

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer

Purity

98.0

Solubility

Ethanol : 5 mg/mL (ultrasonic; warming)

Smiles

C[C@@]12C(C3=C([2H])N=C([2H])C([2H])=C3[2H])=CC[C@]1([C@@]4(CC=C5[C@@](C)([C@]4(CC2)[H])CC[C@@H](C5)O)[H])[H]

Molecular Formula

C24H27D4NO

Molecular Weight

353.53

References & Citations

[1]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26 (28) :4563-71.; Richards J, et al. Interactions of|[2]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26 (28) :4563-71.